<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138979</url>
  </required_header>
  <id_info>
    <org_study_id>Yunwei Wei 2019-09-13</org_study_id>
    <nct_id>NCT04138979</nct_id>
  </id_info>
  <brief_title>Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy</brief_title>
  <official_title>Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, few studies have addressed the link between gut microbiota and breast cancer
      chemotherapy, and previous studies have only provided a link between the gut and breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, few studies have addressed the link between gut microbiota and breast cancer
      chemotherapy, and previous studies have only provided a link between the gut and breast
      cancer.At present, studies on the interaction mechanism between intestinal flora and breast
      cancer mainly focus on two aspects: first, intestinal flora affects the occurrence and
      progress of breast cancer by affecting estrogen metabolism;Second, intestinal flora can
      influence the occurrence and treatment of breast cancer by affecting the regulation of the
      immune system.However, the specific types (or groups) of bacteria that promote the
      occurrence, development and mechanism of breast cancer still need to be further studied.In
      addition, since most of the current clinical studies on microorganisms and breast cancer are
      small sample studies, the accuracy of their conclusions remains to be studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">October 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Transcriptional changes in gut microbiota</measure>
    <time_frame>baseline,1 day,7 day,14 days,22 days,29 days,36 days,44days,51days,58days,66days,73days,80days</time_frame>
    <description>The microbiota measured by 16S rRNA gene</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Microbiota</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>20 healthy volunteers were included in the healthy control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease group</arm_group_label>
    <description>First chemotherapy for breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>First use of chemotherapy after breast cancer</description>
    <arm_group_label>Disease group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients were included according to the inclusion and exclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 65 years

          -  First use of chemotherapy after breast cancer

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Cigarette smoking

          -  Alcohol addiction

          -  Hypertension

          -  Diabetes mellitus

          -  Lipid dysregulation

          -  BMI &gt; 27

          -  Recent (&lt; 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics,
             hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or Chinese
             herbal medicine

          -  History of disease with an autoimmune component, such as MS, rheumatoid arthritis,
             IBS, or IBD

          -  History of malignancy or any gastrointestinal tract surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunwei Wei, doctor</last_name>
    <phone>+86-0451-85553099</phone>
    <email>hydwyw11@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First affiliated hospital of Harbin medical university</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunwei Wei</last_name>
      <phone>+86-0451-85553099</phone>
      <email>hydwyw11@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Luu TH, Michel C, Bard JM, Dravet F, Nazih H, Bobin-Dubigeon C. Intestinal Proportion of Blautia sp. is Associated with Clinical Stage and Histoprognostic Grade in Patients with Early-Stage Breast Cancer. Nutr Cancer. 2017 Feb-Mar;69(2):267-275. doi: 10.1080/01635581.2017.1263750. Epub 2017 Jan 17.</citation>
    <PMID>28094541</PMID>
  </reference>
  <reference>
    <citation>Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dor√© J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010 Mar 4;464(7285):59-65. doi: 10.1038/nature08821.</citation>
    <PMID>20203603</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut microbiota</keyword>
  <keyword>16S rRNA gene</keyword>
  <keyword>breast cancer chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

